BR112023008317A2 - Proteínas de fusão sap fc e métodos de uso - Google Patents
Proteínas de fusão sap fc e métodos de usoInfo
- Publication number
- BR112023008317A2 BR112023008317A2 BR112023008317A BR112023008317A BR112023008317A2 BR 112023008317 A2 BR112023008317 A2 BR 112023008317A2 BR 112023008317 A BR112023008317 A BR 112023008317A BR 112023008317 A BR112023008317 A BR 112023008317A BR 112023008317 A2 BR112023008317 A2 BR 112023008317A2
- Authority
- BR
- Brazil
- Prior art keywords
- sap
- methods
- fusion proteins
- relates
- related diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1716—Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108799P | 2020-11-02 | 2020-11-02 | |
| US202163153777P | 2021-02-25 | 2021-02-25 | |
| PCT/US2021/072168 WO2022094630A1 (en) | 2020-11-02 | 2021-11-01 | Sap fc fusion proteins and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023008317A2 true BR112023008317A2 (pt) | 2024-02-06 |
Family
ID=78771272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023008317A BR112023008317A2 (pt) | 2020-11-02 | 2021-11-01 | Proteínas de fusão sap fc e métodos de uso |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12161692B2 (enExample) |
| EP (1) | EP4237083A1 (enExample) |
| JP (1) | JP7856264B2 (enExample) |
| KR (1) | KR20230097061A (enExample) |
| AU (1) | AU2021368272A1 (enExample) |
| BR (1) | BR112023008317A2 (enExample) |
| CA (1) | CA3196766A1 (enExample) |
| IL (1) | IL302388A (enExample) |
| MX (1) | MX2023005063A (enExample) |
| WO (1) | WO2022094630A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3012453B1 (fr) | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| BR112023008317A2 (pt) | 2020-11-02 | 2024-02-06 | Attralus Inc | Proteínas de fusão sap fc e métodos de uso |
| WO2024153768A1 (en) * | 2023-01-20 | 2024-07-25 | Boehringer Ingelheim International Gmbh | Il-12 fc fusion proteins |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9317120D0 (en) | 1993-08-17 | 1993-09-29 | Royal Postgrad Med School | Human serum amyloid p component |
| AU2002225772A1 (en) | 2000-11-27 | 2002-06-03 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease |
| US9200079B2 (en) * | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| CA2682605A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| GB0712503D0 (en) | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
| EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| HUE041034T2 (hu) | 2009-06-17 | 2019-05-28 | Promedior Inc | SAP-variánsok és alkalmazásuk |
| WO2011119608A1 (en) | 2010-03-26 | 2011-09-29 | University Of Tennessee Research Foundation | Peptides that specifically target amyloid deposits |
| CN104203981A (zh) | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| WO2013096847A1 (en) | 2011-12-21 | 2013-06-27 | Promedior, Inc. | Serum amyloid p-antibody fusion proteins |
| EP3027647A4 (en) | 2013-07-31 | 2017-01-04 | Amgen Inc. | Stabilization of fc-containing polypeptides |
| FR3012453B1 (fr) | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| US9683017B2 (en) | 2014-07-17 | 2017-06-20 | University Tennessee Research Foundation | Inhibitory peptides of viral infection |
| US10213506B2 (en) | 2014-08-26 | 2019-02-26 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
| US20200148779A1 (en) | 2017-05-25 | 2020-05-14 | Bristol-Myers Squibb Company | MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH |
| JP2021521273A (ja) | 2018-04-12 | 2021-08-26 | メディアファーマ エス．アール．エル． | Ｌｇａｌｓ３ｂｐ抗体−薬剤結合体及びがん治療のためのその使用 |
| BR112023008317A2 (pt) | 2020-11-02 | 2024-02-06 | Attralus Inc | Proteínas de fusão sap fc e métodos de uso |
-
2021
- 2021-11-01 BR BR112023008317A patent/BR112023008317A2/pt unknown
- 2021-11-01 MX MX2023005063A patent/MX2023005063A/es unknown
- 2021-11-01 WO PCT/US2021/072168 patent/WO2022094630A1/en not_active Ceased
- 2021-11-01 KR KR1020237016378A patent/KR20230097061A/ko active Pending
- 2021-11-01 EP EP21815085.2A patent/EP4237083A1/en active Pending
- 2021-11-01 JP JP2023526513A patent/JP7856264B2/ja active Active
- 2021-11-01 US US17/516,601 patent/US12161692B2/en active Active
- 2021-11-01 CA CA3196766A patent/CA3196766A1/en active Pending
- 2021-11-01 IL IL302388A patent/IL302388A/en unknown
- 2021-11-01 AU AU2021368272A patent/AU2021368272A1/en active Pending
-
2024
- 2024-10-25 US US18/927,701 patent/US20250152667A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220160831A1 (en) | 2022-05-26 |
| WO2022094630A1 (en) | 2022-05-05 |
| US20250152667A1 (en) | 2025-05-15 |
| CA3196766A1 (en) | 2022-05-05 |
| AU2021368272A1 (en) | 2023-06-08 |
| MX2023005063A (es) | 2023-05-12 |
| KR20230097061A (ko) | 2023-06-30 |
| JP7856264B2 (ja) | 2026-05-11 |
| IL302388A (en) | 2023-06-01 |
| US12161692B2 (en) | 2024-12-10 |
| JP2023550287A (ja) | 2023-12-01 |
| AU2021368272A9 (en) | 2025-03-13 |
| EP4237083A1 (en) | 2023-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20082648A (es) | Anticuerpos anti-sirpa y métodos de utilización de los mismos | |
| CL2021000873A1 (es) | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas. | |
| CY1124153T1 (el) | Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127 | |
| MX2021013126A (es) | Variantes de il-15 y usos de las mismas. | |
| SA521422089B1 (ar) | c أجسام مضادة مكتسبة للسمة البشرية ضد مجموعة | |
| MX2020008336A (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. | |
| CO2019003945A2 (es) | Proteínas de fusión heterodiméricas biespecíficas que contienen proteínas de fusión fc il-15/il-15rα y fragmentos de anticuerpo pd-1 | |
| BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
| MX2019010408A (es) | Formulacion de anticuerpo monoclonal anti-vrs. | |
| CR20220545A (es) | ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2) | |
| EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
| MX2022004291A (es) | Anticuerpos dirigidos a tirosina cinasa 3 relacionada con fms (flt3) y uso de los mismos. | |
| MX2024005705A (es) | Composiciones de liquidos ionicos. | |
| JOP20230311A1 (ar) | أجسام مضادة لـ sirp-ألفا | |
| JOP20210166A1 (ar) | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r | |
| CL2023001052A1 (es) | Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea | |
| MX2021008207A (es) | Proteínas de fusión multifuncionales y usos de las mismas. | |
| CO2022005587A2 (es) | Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas | |
| EA202191175A1 (ru) | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры | |
| MX2019006444A (es) | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. | |
| MX2023005063A (es) | Proteinas de fusion sap fc y metodos de uso. | |
| CO2023001559A2 (es) | Anticuerpos fgfr3 y métodos de uso | |
| MX2021010061A (es) | Proteínas de fusión fc con dominio extracelular de cd80 para tratar tumores negativos para pd-l1. | |
| UY36262A (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |